

E.D. Bateman has received lecture fees and remuneration from Novartis for serving on an advisory board, and his institution for participation in clinical trials.

G.T. Ferguson has received industry funding from Novartis to perform clinical trials, with payments for study activities being in excess of USD 50 000 over the last 5 years. The author has received payment from Novartis for consulting at advisory boards for less than USD 10 000 over the last 5 years.

N. Barnes has served on advisory boards or given lectures for Almirall, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, NAPP and Teva. The author has received research grants from Almirall, AstraZeneca, GlaxoSmithKline, Takeda, Boehringer Ingelheim and Chiesi.

N. Gallagher is an employee of Novartis Pharma AG, and holds stocks and shares with the company.

Y. Green is employed by Novartis.

M. Henley is employed by Novartis.

D. Banerji is an employee of Novartis.